granted
on 10 Jul 2024
Last Applicant/ Owned by
Route 206 & Province Line Road
Princeton
NJ
08543
Serial Number
90271712 filed on 22nd Oct 2020
Registration Number
N/A
Correspondent Address
Marilyn F. Kelly
Marilyn F. Kelly BRISTOL-MYERS SQUIBB COMPANY
TRADEMARK DEPT., MAILSTOP D.4243
PRINCETON, NJ 08648-4000
United States
Filing Basis
1. intent to use
2. intent to use current
Disclaimer
NO DATA
Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloprol Read More
Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely, T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use; Pharmaceutical preparations for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; monoclonal antibodies
N/A
N/A
No 90271712
No Service/Collective Mark
No
No
No
No
No
No
No
No
No
Status Date | Action Taken |
---|---|
10th Jul 2024 | SOU EXTENSION 5 FILED |
10th Jul 2024 | SOU EXTENSION 5 GRANTED |
10th Jul 2024 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
10th Jul 2024 | SOU TEAS EXTENSION RECEIVED |
05th Jan 2024 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
03rd Jan 2024 | SOU EXTENSION 4 FILED |
03rd Jan 2024 | SOU TEAS EXTENSION RECEIVED |
03rd Jan 2024 | SOU EXTENSION 4 GRANTED |
02th Aug 2023 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
02th Aug 2023 | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |